Drug-coated balloon treatment of complex femoropopliteal disease yields favorable and durable outcomes at 5 years.

Abstract

Key Points Randomized clinical trials have previously demonstrated drug‐coated balloon (DCB) treatment of femoropopliteal disease reduces the odds of clinically driven target lesion revascularization (CD‐TLR) by 60%–70% at 2–3 years compared to balloon angioplasty alone. The single‐arm IN.PACT Global Study demonstrates clinical outcomes observed at 2 years tend to remain durably stable through 5 years of follow‐up. Approximately three‐quarters of patients undergoing DCB treatment of relatively complex femoropopliteal disease had freedom from CD‐TLR at 5 years.